PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Rapidly Evolving Stem Cells Market Opens Up Doors for Related Research Tools Says Frost & Sullivan - Lack of venture capital infusions threatens to slow pace of research and market development - Drugdiscovery.Frost.com
Rapidly Evolving Stem Cells Market Opens Up Doors for Related Research Tools Says Frost & Sullivan

 

NewswireToday - /newswire/ - London, United Kingdom, 2012/01/20 - Lack of venture capital infusions threatens to slow pace of research and market development - Drugdiscovery.Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Stem cell research is very dynamic with research trends, focus, and approaches evolving extremely rapidly. The tool market has to quickly adapt to these challenges and develop innovative tools that address and accelerate research accomplishments.

New analysis from Frost & Sullivan (drugdiscovery.frost.com), Strategic Analysis of the European Stem Cell Research Tools Market, finds that the market earned revenues of $131.7 million in 2010 and estimates this to reach $322.0 million in 2017. The segments covered include: bio-imaging and microscopy, cell biology tools, immunochemical, molecular biology tools, and protein biochemistry tools.

"Firms with the capacity to supply tools for stem cell research will increase as the science matures," notes Frost & Sullivan Senior Research Analyst Divyaa Ravishankar. "Soon demand and supply will achieve a degree of equilibrium."

Already, a sizeable stem cell research products market has emerged. Another positive sign for the market has been enhanced industry- academic collaboration.

A key step forward has been the stem cell regulations in a few countries allowing the use of certain cell lines. In some countries such as France, for instance, stem cell regulations are being renewed for the procurement and use of stem cells.

"Such trends indicate the potential for a regulatory climate that would be far less restrictive than the current scenario," adds Divyaa Ravishankar. "This, together with the prospect of diverse applications within the healthcare arena, is bolstering the future of the market."

However, the lack of venture capitalists (VC) poses a grave challenge. VC funding is driven by investment concerns, with companies bidding to double their money every few years in order to return revenue to the fund's investors. As a high risk venture, stem cell technology does not exactly present an attractive investment proposition.

"While these are financial concerns, from the technological standpoint, the challenge remains to understand the basic biology behind stem cells," remarks Divyaa Ravishankar. "There is an urgent need to design and develop specific technology platforms that enhance the production, genetic stability and integration of transplanted cells."

If you are interested in more information on this study, please send an e-mail with your contact details to Janique Morvan, Corporate Communications, at janique.morvan[.]frost.com.

Strategic Analysis of the European Stem Cell Research Tools Market is part of the Clinical Diagnostics Growth Partnership Services programme, which also includes research in the following markets: European PCR Reagent Market for Research and Clinical Diagnostics and European Next Generation Sequencing Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit frost.com.

Strategic Analysis of the European Stem Cell Research Tools Market / M72F-55

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Rapidly Evolving Stem Cells Market Opens Up Doors for Related Research Tools Says Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Janique Morvan - Frost.com 
+33(0)1 42 81 20 37 janique.morvan[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Al Rowaad Advocates & Legal Consultants

Visit  1Click Games





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)